Acadia Pharmaceuticals Inc. (ACAD) was reiterated a ‘Buy’ by Jefferies analysts on Thursday. The broker also cut its price target on the stock to $47 from $50.
ACAD shares recently lost 9.39 to $35.37. In the past 52 weeks, shares of San Diego, California-based biopharmaceutical company have traded between a low of $15.64 and a high of $46.48. Shares are up 62.59% year-over-year and 40.98% year-to-date.
Alibaba Group Holding Limited (BABA) was reiterated as ‘Buy’ with a $98 from $105.10 price target on Thursday by Deutsche Bank (DB).
Alibaba Group Holding, currently valued at $203.62 billion, has a median Wall Street price target of $112.00 with a high target of $136.00. Approximately 7.34 million shares have already changed hands, compared to the stock’s average daily volume of 16.24 million.
In the past 52 weeks, shares of the online and mobile commerce company have traded between a low of $80.03 and a high of $120.00 with the 50-day MA and 200-day MA located at $89.04 and $97.62 levels, respectively. Additionally, shares of BABA trade at a P/E ratio of 1.22 and have a Relative Strength Index (RSI) and MACD indicator of 35.01 and -1.89, respectively.
BABA currently prints a year-to-date loss of 21.12%.
Shares of Ocera Therapeutics, Inc. (OCRX) are up $0.40 at $4.60, after Stifel this morning lowered its price target on the shares to $15 from $17, and reiterated a ‘Buy’ rating.
Stifel’s price objective suggests a potential upside of 226% from the stock’s current price.
Ocera shares are down 70.28% year-over-year, while the S&P 500 has gained 10.50%.
Intel Corporation (INTC) rating of ‘Buy’ was reiterated today at MKM Partners with a price target decrease of $40 from $45 (versus a $32.33 previous close).
INTC shares recently lost $1.57 to $30.76. Shares of the world’s biggest chipmaker are down 4.60% after the company cut its Q1/15 revenue forecast. Intel said businesses just aren’t upgrading their PCs as much as expected.
Du Pont (DD) was reiterated as ‘Sector Perform’ and the price target was decreased to $67 from $68 at RBC Capital Markets.
E. I. du Pont de Nemours and Company (DD) shares are currently priced at 20.44x this year’s forecasted earnings compared to the industry’s 17.83x earnings multiple. Ticker has a PEG and forward P/E ratio of 2.32 and 17.43, respectively. Price/Sales for the same period is 2.06 while EPS is $3.92. Currently there are 6 analysts that rate DD a ‘Buy’, 15 rate it a ‘Hold’. No analyst rates it a ‘Sell’. DD has a median Wall Street price target of $72.00 with a high target of $91.00.
In the past 52 weeks, shares of Wilmington, Delaware-based company have traded between a low of $63.70 and a high of $80.08 and are now at $80.03. Shares are up 23.37% year-over-year and 7.91% year-to-date.